Backgrounds/Aims: The protective effect of everolimus (EVR) in hepatocellular carcinoma (HCC) patients who receive liver transplantation in terms of reducing the recurrence has not been sufficiently investigated in clinical trials. In this second stage of our ongoing study, we intend to analyze the effects of EVR as an immunosuppressant, when it is started in the early phase after living donor liver transplantation (LDLT), on HCC recurrence in patients with HCC within the University of California at San Francisco (UCSF) criteria. Methods: From January 2011 to June 2013, a total of 250 patients underwent LDLT for HCC at our institute. The patients with HCC within the UCSF criteria were included in the study and divided in two groups depending upon the postoperative immunosuppression. Group A: HCC patients that received EVR+TAC based immunosuppressive regimen (n=37). Group B: HCC patients that received standard TAC based immunosuppressive regimen without EVR (n=29). The target trough level for EVR was 3 to 5 ng/ml while for TAC it was 8-10 ng/ml. Results: For group A patients, the mean trough level of the EVR was 3.47±1.53 ng/ml (range, 1.5-11.2) with a daily dose of 1.00±0.25 mg/day. For group A and B, the average TAC trough levels were 6.97±3.98 ng/ml (range, 2.50 to 11.28 ng/ml) and 6.93±2.58 (range, 2-16.30), respectively. The 1-year, 3-year and 4-year overall survival achieved for Group A patients was 94.95%, 86.48% and 86.48%, respectively while for Group B patients it was 82.75%,68.96%, and 62.06%, respectively (p=0.0217). Conclusions: EVR use in liver transplant recipients in the early stage after transplantation reduces the HCC recurrence rates in HCC patients within the UCSF criteria. 
INTRODUCTION
Liver transplantation is an acceptable modality of treatment for unresectable HCC that falls within acceptable criteria such as the Milan criteria 1 or the UCSF criteria 2 with 5-year survival rates of ＞70%. 3 In Asia, LDLT is a quick source of donor liver allografts for the waitlisted HCC patients and patients with end-stage-liver disease (ESLD) as the chances of getting deceased organs are dismal. 4 Because of continued increase in the cohort population of HCC patients who require liver transplantation, many clinical studies in the recent era have described and evaluated the expanded criteria for HCC and the outcome of such patients after LDLT. [5] [6] [7] [8] [9] However, recurrence of HCC remains a problem even after LDLT, and the risk is higher for HCC recipients beyond the Milan criteria. 10 Recurrence of HCC has been reported to occur in approximately 10-30% of liver transplant recipients over 5 years post transplantation among the patients within the Milan criteria, and the risk increases further among recipients of extended criteria organs. 10, 11 The role of post-transplant immunosuppression in the recurrence of HCC as well as de novo malignancy in addition to renal dysfunction and hepatitis C virus (HCV) recurrence is well documented. 12, 13 Promotion of tumor growth (adenocarcinoma) by both, cyclosporine and tacrolimus, through a non-immunologically mediated mechanism related to augmented transforming growth factor-beta production has been demonstrated in vitro and in animal studies. 14, 15 High levels of calcineurin inhibitors (CNIs) in the early post-transplant period have been shown to be an independent risk factor for HCC recurrence. The apoptotic regulator Aakt, a serine-threonine kinase, is activated in many cancers, and its downregulation by m-TOR inhibitors has been found to interfere with tumor growth in various cancers as well as in HCC. 17 EVR is now a commonly used mTOR inhibitor, and its safety during the early phase after LDLT has been recently confirmed.
In our previous study of 43 sequential liver transplant recipients, we proved its safety without any hepatic arterial complications as well as its beneficial role in recipients with renal dysfunction prior to liver transplantation. 18 In this study, we also assessed the proposed role of EVR in reducing HCC recurrence. Although few studies have compared the long-term survival in liver transplant recipients with HCC who received sirolimus and those who received sirolimus-free immunosuppression, such studies on EVR are limited to a few institutional reports.
In this retrospective and prospective analysis, which is a continuation of our previous study, 18 we aim to determine the possible impact of EVR in reducing the recurrence of HCC within the UCSF criteria when used in the early phase after LDLT along with Tacrolimus (TAC) based primary immunosuppression.
MATERIALS AND METHODS
From January 2011 to June 2013, a total of 250 patients underwent LDLT at the institute of China Medical University Hospital, Taiwan. The patients with HCC within the UCSF criteria were included in this study and they were divided into two groups depending upon postoperative immunosuppression.
Group A: HCC patients who received EVR+TAC based immunosuppressive regimen (n=37) [continuation of our previous study 18 ].
Group B: HCC patients who received standard TAC based immunosuppressive regimen without EVR (n=29). Overall Survival and disease-free survival In this study, the overall survival was calculated till the last follow-up period or the death of the recipient starting from LDLT. Disease free survival was defined as the time period from LDLT to the date of the diagnosis of recurrence. The overall and disease-free survival was then compared between the study cohort and the historical control group.
Recipient surgery, post-operative follow up, and immunosuppressive protocol All patients with HCV-related HCC underwent splenectomy in addition to total hepatectomy as per the institution's protocol. After the recipients were discharged with stable liver function, they were required to follow up once a week for the 1st month, every fortnight for the next two months, and then as per the recipient's biochemical profile. Every three months, the blood level of AFP and an abdominal USG were performed for the 1 st year.
The immunosuppressive protocol was the same as described in our previous study. 18 EVR was started as early as the 4 th to 21 st post-operative day after LDLT. The target trough level of EVR was 3 to 5 ng/ml, while the target trough level of TAC was 8-10 ng/ml in group A patients, whereas group B patients received only TAC based immunosuppression with similar target trough levels.
Statistical analysis
Descriptive statistics were computed for age, model for end-stage liver disease (MELD) score, and laboratory data.
These statistics were then examined by independent two sample t-tests. Results were presented as mean values±standard deviation (SD). All tests were two-sided, and a p value ＜0.05 was considered statistically significant.
Cox regression model was used to plot the graph. ng/ml) with a daily dose of 1.00±0.25 mg/day. In groups A and B, the average TAC trough levels were 6.97±3.98 ng/ml (range, 2.50 to 11.28 ng/ml) and 6.93±2.58 ng/ml (range, 2-16.30 ng/ml), respectively ( Table 2 ).
RESULTS

Group
The 1-year, 3-year, and 4-year overall survival rates achieved in Group A patients were 94.95%, 86.48%, and 86.48%, respectively (Table 3) , while the 1-year, 3-year, and 4-year overall survival rates achieved in Group B patients were 82.75%, 68.96%, and 62.06%, respectively (p=0.0217). The survival graph is shown in Fig. 1 . Patterns of recurrence of HCC after LDLT and survival Five patients (13.51%) from group A expired. Four patients had extrahepatic recurrence whereas one patient died of sepsis. In group B, eleven patients expired, out of which 7 patients expired due to extrahepatic metastasis of HCC whereas 4 patients died secondary to overwhelming sepsis. All recurrences developed in the extra-hepatic region. None of the studied patients from either of the two groups developed an intra-hepatic recurrence. Bone marrow suppression and other adverse effects The leucocyte count was significantly reduced after EVR and tacrolimus combination was used. The mean leucocyte count at the start of EVR was 9.38×10 3 cells/mm 3 .
Effects on renal function and metabolism-
In group A recipients, the leucocyte count reduced to 4.95×10 3 cells/mm 3 (p＜0.001) at 6 months post-transplantation whereas no such significant drop in the leucocyte count was noticed in group B recipients.
Pancytopenia requiring temporary discontinuation of EVR occurred in 1 recipient belonging to group A, while no significant pancytopenia was noticed in group B recipients.
None of the patients developed HAT, incisional hernia, or wound infections, which were the initial concerns.
Stomatitis was the most common adverse effect, and it occurred in 14 of the recipients. In the present study population, five patients underwent salvage transplantation. The 3-year survival was 80% in this subgroup (4 of 5). Whether EVR has a direct impact on survival after salvage transplantation remains to be proven. But, this finding suggests an improved overall survival of these patients, who had intra-hepatic recurrence after initial liver resection followed by LDLT.
Salvage transplantation subgroup
However, a long-term follow up of this subgroup is required to prove the role of EVR in reducing the recurrence.
The aim of our previous study 18 was to prove the safety of EVR when used in the early phase after LDLT and its efficacy in improving renal function or preventing further deterioration. This study was a continuation of our initial observation in the HCC subgroup, and hence, the dose of EVR was as per the initial protocol. But, with a 4-year survival of 86.48% in the UCSF group, the role and space of this observation can further be expanded by conducting trials of immunosuppressive regimens containing an increased EVR dose with minimal CNI exposure.
In conclusion, EVR use in liver transplant recipients in the early stage after transplantation reduces the HCC recurrence rates among HCC patients within the UCSF criteria. More randomized controlled trials in this regard with higher target trough levels of EVR are warranted to strengthen this finding. The use of EVR was safe without any evidence of HAT or wound infection.
